Search Results 681-690 of 19316 for Hemoglobin

  1. A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

    progression has been demonstrated in such lesions. - Have adequate organ function as defined in Hematological: ANC ≥1500/?L, Platelets ≥100 000/?L; Hemoglobin ...

  2. Baricitinib In Relapsing Giant Cell Arteritis - Mayo Clinic

    Hemoglobin < 10 grams/deciliter; Total white blood cell count (WBC) < 2500 cells/μL); Neutropenia (absolute neutrophil count [ANC] < 1200 cells/μL; Lymphopenia ...

  3. Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma that has been Removed by Surgery - Mayo Clinic

    Pregnant or breastfeeding. White blood cell (WBC) ≥ 3,000/uL; Absolute neutrophil count (ANC) ≥ 1,500/uL; Platelets ≥ 100 x 10^3/uL; Hemoglobin ≥ 10 g/dL ...

  4. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - Mayo Clinic

    Total bilirubin > 2 mg/dL (except for subjects with an established diagnosis of Gilbert's syndrome, if hemoglobin and reticulocyte count are within normal ...

  5. Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL (the use of transfusion or other intervention is allowed); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ...

  6. Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM) - Mayo Clinic

    Hemoglobin > 8 g/dL;; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 20 times the upper limit of the institutional normal ranges. Women ...

  7. Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas - Mayo Clinic

    - Hemoglobin ≥ 9.0 g/dL or > 5.6 mmol/L (transfusion is acceptable to meet this ;criterion) - Serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min ...

  8. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

    Patients must have hemoglobin ≥ 8 g/dL within 28 days prior to registration. Patients may have received transfusion if greater than 7 days prior to ...

  9. Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer - Mayo Clinic

    * hemoglobin ≥ 9g/dL (without use of erythropoietin; without packed RBC transfusion within preceding 2 weeks) * platelet count ≥100,000/?cL * total ...

  10. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer - Mayo Clinic

    Adequate hematology without transfusional support (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3). Blood transfusion or growth ...